Skip to main content
. 2015 Nov 25;16(8):563–571. doi: 10.5152/AnatolJCardiol.2015.6272

Table 4.

Univariate and multivariate predictors of atrial fibrillation recurrence between 1 week and 30 days after electrical cardioversion

Variable Univariate analysis Multivariate analysis
OR [CI 95%] P OR [CI 95%] P
Age, years 1.07 (0.96–1.19) 0.24
Gender, male=1 0.99 (0.19–4.94) 0.9
AF history, years 1.15 (0.89–1.49) 0.3
AF episode duration before CV, days 1.003 (0.99–1.02) 0.6
Coronary artery disease 3.42 (0.38–31.08) 0.3
Diabetes 1.43 (0.25–8.23) 0.7
Chronic obstructive pulmonary disease 0.95 (0.09–9.31) 0.9
Chronic kidney disease 2.28 (0.39–13.05) 0.4
Left ventricular ejection fraction, % 0.86 (0.72–1.03) 0.09 0.79 (0.54–1.15) 0.2
Left atrial diameter, mm 1.06 (0.85–1.32) 0.6
Left atrial emptying fraction <38% 3.18 (0.62–16.24) 0.16 10.35(0.29–36.24) 0.2
NPT I, nmol/L 1.11 (0.96–1.28) 0.17 0.96 (0.65–1.41) 0.8
NPT II, nmol/L 1.31 (0.99–1.72) 0.05 1.79 (0.61–5.24) 0.3
NPT III, nmol/L 1.26 (0.96–1.65) 0.09 1.32 (0.66–2.61) 0.4
IL-6 I, pg/mL 1.09 (0.82–1.45) 0.5
IL-6 II, pg/mL 0.98 (0.81–1.17) 0.8
IL-6 III, pg/mL 0.93 (0.62–1.41) 0.7
ACEI/ARB 2.85 (0.56–14.52) 0.21
Statin 0.75 (0.08–7.12) 0.8

ACEI - angiotensin-converting enzyme inhibitor; AF - atrial fibrillation; ARB - angiotensin II receptor blocker; CI - confidence interval; CV - electrical cardioversion; IL-6 - interleukin-6; NPT - neopterin; OR - odds ratio